Click Here to Register »

2018 Executive Sponsors

Adaptive Biotechnologies
Imaging Endpoints

2018 Associate Sponsors

Defined health

2018 Exhibitors

Axio Research
Caprion
Cytel
Intrinsic Imaging
KIYATEC Inc
Mitra Biotech
NeoGenomics
Personalis

2018 Supporting Partners

Trout Group

2018 Educational Partners

CIMT
CRI
SITC

2018 Media Partners

BioPharm Insight
BioPharma Dive
CanBiotech
Patient Empowerment
Pharmalicensing
Pharmaphorum
PharmaVOICE
Technology Networks

The Premier Meeting Across all Stakeholders in Immuno-Oncology

 

Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including:

  • Discovery / Preclinical Science

  • Translational Science

  • Clinical Development

  • Business Aspects

  • Investor Relations

  • Emerging Technologies

  • Biomarkers / Diagnostics

  • Trends in the Field

2018 IO360 main speakers

Overview

Dr Axel Hoos, GSK and Dr James Gulley, NCI, together led the design of the 4th annual Immuno-Oncology 360° program to include 45 speakers and over 30 talks. We are delighted to announce that Dr Andrew Baum  is confirmed as the investor relations plenary keynote.

Featured Speakers

IO360 Featured Speakers

Immuno-Oncology 360° provides the most up-to-date research, data and progress to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof​
  • Receive the latest pre-clinical, translational and clinical data from academic and industry
  • Identify and gain a greater understanding of what assets are available for potential combinations  
  • Create and prioritize strategies targeted toward specific tumor types​
  • Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
  • Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
  • Hear reports on industry trends from Endpoint News and BioCentury Innovations and a progress update on the Cancer Moonshot
  • Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies

Please contact us at service@tcfllc.org if you have any questions. Thank you and we look forward to seeing you in February.

Sincerely,​

kate-bw-3

Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director

Meredith Sands
Executive Director, Business Development

onaleesmith-bw

Onalee Smith
Marketing Manager

elizabeth-bard-bw-2

Elizabeth Bard
Business Development Manager

geeta-new-bw

Geeta Bachani
Business Development Manager

bridget_new_bw2

Bridget Murphy
Senior Conference Planner

Tara Fennelly
Marketing Associate


Dr Daniel Chen, Genentech delivered a talk on cancer immunity cycle at IO360° 2017

Dr Patricia Keegan, FDA discussed Modified RECIST 1.1 at IO360° 2017

Trends & Collaborations Panel at IO360° 2017: From Left to Right: Dr Ramy Ibrahim, Parker Research Institute for Cancer Immunotherapy, Dr David Wholley, Foundation for the National Institutes of Health, Dr Jill O’Donnell-Tormey, Cancer Research Institute, Dr Daniel Chen, Genentech